For those interested in cannabis industry events, Seyfarth attorneys will be participating in the following webinar programs and we invite you to join.

Thursday, October 1 – “CBD News You Can Use: FDA’s Progress and Other Updates” hosted by Seyfarth

This program offers an overview of the distinction between cannabis, hemp, marijuana, and CBD; a

Hemp production, unlike much of the farming industry, has not declined due to COVID-19.  Meanwhile, certain CBD companies have wasted no time in making unsubstantiated claims related to COVID-19.  In turn, FDA and FTC enforcement has ramped up.

As the pandemic rages on, the CBD industry continues to grow as it did before the crisis,

When we all sheltered in place in mid-March, social media accounts everywhere reflexively joked how marijuana use was about to skyrocket like wine consumption and On Demand streaming. True to form, recreational marijuana retailers in LA and several markets in the US where stores remained open saw an immediate spike in sales; there was a

In response to the drastic economic impact COVID-19 has had on small businesses in recent weeks, President Trump announced that the Small Business Administration (SBA) was authorized to provide $50 billion in low-interest loans – more than double the amount of loans provided by the SBA in 2019 – to keep them operating during the

The continued efforts of federal, state, and local governments to legalize cannabis, both in medical and recreational uses, leaves many potential impacts, including environmental law and regulatory issues in the manufacturing, processing, and distribution of cannabis products.
Continue Reading Future Enterprises and Environmental Impacts in the Cannabis Industry

In its largest mass enforcement action involving cannabidiol (CBD) yet, the U.S. Food & Drug Administration (FDA) announced on November 25 the issuance of 15 warning letters to various companies for illegally selling products containing CBD.  In addition to the letters, the FDA published a revised Consumer Update detailing safety concerns about CBD products more broadly.  Notably, the FDA commented that it “plans to provide an update on its progress regarding the agency’s approach to these [CBD] products in the coming weeks.”  Previously, the FDA had indicated it would generate a report by this Fall.  Finally, the FDA reiterated that “[i]t is currently illegal to market CBD by adding it to a food or labeling it as a dietary supplement.”  Unlike hemp derivatives– hulled hemp seed, hemp seed protein powder, and hemp seed oil–which were added to the FDA’s Generally Recognized as Safe (GRAS) inventory, the FDA also confirmed that, at this time, CBD is not generally recognized as safe for use in human or animal food.
Continue Reading FDA Stresses CBD Safety Concerns in 15 Warning Letters and Revised Consumer Update

Welcome back to The Week in Weed, your Friday look at what’s happening in the world of legalized marijuana.

First, a point of personal pride.  The Blunt Truth started in February 2016, with the slightly crazy idea that a BigLaw firm could talk about marijuana on a regular basis.  As of this week, we’ve

Georgia Governor Brian Kemp signed a bill on April 17, entitled Georgia’s Hope Act (HB 324), allowing in-state production and sale of marijuana oil for medical use. Before this bill, Georgia only allowed citizens with a narrow list of specific medical conditions to possess cannabis oil with less than five percent THC, but